Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

New targets for old drugs: cardiac glycosides inhibit atrial-specific K2P3.1 (TASK-1) channels.

Schmidt C, Wiedmann F, Gaubatz AR, Ratte A, Katus HA, Thomas D.

J Pharmacol Exp Ther. 2018 Apr 11. pii: jpet.118.247692. doi: 10.1124/jpet.118.247692. [Epub ahead of print]

2.

Extracellular vesicles mediate intercellular communication: Transfer of functionally active microRNAs by microvesicles into phagocytes.

Claßen L, Tykocinski LO, Wiedmann F, Birr C, Schiller P, Tucher C, Krienke S, Raab MS, Blank N, Lorenz HM, Schiller M.

Eur J Immunol. 2017 Sep;47(9):1535-1549. doi: 10.1002/eji.201646595. Epub 2017 Jul 20.

PMID:
28665018
3.

Stretch-activated two-pore-domain (K2P) potassium channels in the heart: Focus on atrial fibrillation and heart failure.

Schmidt C, Wiedmann F, Kallenberger SM, Ratte A, Schulte JS, Scholz B, Müller FU, Voigt N, Zafeiriou MP, Ehrlich JR, Tochtermann U, Veres G, Ruhparwar A, Karck M, Katus HA, Thomas D.

Prog Biophys Mol Biol. 2017 Nov;130(Pt B):233-243. doi: 10.1016/j.pbiomolbio.2017.05.004. Epub 2017 May 16.

PMID:
28526353
4.

Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy.

Schmidt C, Wiedmann F, Zhou XB, Heijman J, Voigt N, Ratte A, Lang S, Kallenberger SM, Campana C, Weymann A, De Simone R, Szabo G, Ruhparwar A, Kallenbach K, Karck M, Ehrlich JR, Baczkó I, Borggrefe M, Ravens U, Dobrev D, Katus HA, Thomas D.

Eur Heart J. 2017 Jun 7;38(22):1764-1774. doi: 10.1093/eurheartj/ehw559.

PMID:
28057773
5.

A Simple, Non-Invasive Score to Predict Paroxysmal Atrial Fibrillation.

Kallenberger SM, Schmid C, Wiedmann F, Mereles D, Katus HA, Thomas D, Schmidt C.

PLoS One. 2016 Sep 28;11(9):e0163621. doi: 10.1371/journal.pone.0163621. eCollection 2016.

6.

Incidental finding of a giant intracardiac angioma infiltrating both ventricles in a 35-year-old woman: a case report.

Hirschberg K, Wiedmann F, Zitron E, Fortner P, Riffel JH, Chorianopoulos E, Gdynia G, Mechtersheimer G, Andrassy M, Szabó G, Arif R, Katus HA, Buss SJ.

J Med Case Rep. 2016 Apr 12;10:94. doi: 10.1186/s13256-016-0860-4.

7.

Therapeutic targeting of two-pore-domain potassium (K(2P)) channels in the cardiovascular system.

Wiedmann F, Schmidt C, Lugenbiel P, Staudacher I, Rahm AK, Seyler C, Schweizer PA, Katus HA, Thomas D.

Clin Sci (Lond). 2016 May;130(9):643-50. doi: 10.1042/CS20150533. Review.

PMID:
26993052
8.

Response to Letter Regarding Article, "Upregulation of K2P3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation".

Schmidt C, Wiedmann F, Voigt N, Zhou XB, Heijman J, Lang S, Albert V, Kallenberger S, Ruhparwar A, Szabó G, Kallenbach K, Karck M, Borggrefe M, Biliczki P, Ehrlich JR, Baczkó I, Lugenbiel P, Schweizer PA, Donner BC, Katus HA, Dobrev D, Thomas D.

Circulation. 2016 Mar 15;133(11):e440-1. doi: 10.1161/CIRCULATIONAHA.115.020662. No abstract available.

9.

Upregulation of K(2P)3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation.

Schmidt C, Wiedmann F, Voigt N, Zhou XB, Heijman J, Lang S, Albert V, Kallenberger S, Ruhparwar A, Szabó G, Kallenbach K, Karck M, Borggrefe M, Biliczki P, Ehrlich JR, Baczkó I, Lugenbiel P, Schweizer PA, Donner BC, Katus HA, Dobrev D, Thomas D.

Circulation. 2015 Jul 14;132(2):82-92. doi: 10.1161/CIRCULATIONAHA.114.012657. Epub 2015 May 7.

10.

Cloning, functional characterization, and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure.

Schmidt C, Wiedmann F, Langer C, Tristram F, Anand P, Wenzel W, Lugenbiel P, Schweizer PA, Katus HA, Thomas D.

Heart Rhythm. 2014 Oct;11(10):1798-805. doi: 10.1016/j.hrthm.2014.06.020. Epub 2014 Jun 18.

PMID:
24952150
11.

Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.

Schmidt C, Wiedmann F, Schweizer PA, Katus HA, Thomas D.

Eur J Pharmacol. 2014 Sep 5;738:250-5. doi: 10.1016/j.ejphar.2014.05.056. Epub 2014 Jun 10. Review.

PMID:
24927994
12.

Cardiac expression and atrial fibrillation-associated remodeling of K₂p2.1 (TREK-1) K⁺ channels in a porcine model.

Schmidt C, Wiedmann F, Tristram F, Anand P, Wenzel W, Lugenbiel P, Schweizer PA, Katus HA, Thomas D.

Life Sci. 2014 Mar 3;97(2):107-15. doi: 10.1016/j.lfs.2013.12.006. Epub 2013 Dec 15.

PMID:
24345461
13.

Functional characterization of zebrafish K2P18.1 (TRESK) two-pore-domain K+ channels.

Rahm AK, Wiedmann F, Gierten J, Schmidt C, Schweizer PA, Becker R, Katus HA, Thomas D.

Naunyn Schmiedebergs Arch Pharmacol. 2014 Mar;387(3):291-300. doi: 10.1007/s00210-013-0945-1. Epub 2013 Dec 6.

PMID:
24311292
14.

Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels.

Schmidt C, Wiedmann F, Schweizer PA, Becker R, Katus HA, Thomas D.

Eur J Pharmacol. 2013 Dec 5;721(1-3):237-48. doi: 10.1016/j.ejphar.2013.09.029. Epub 2013 Sep 23.

PMID:
24070813
15.

Anti-KCNQ1 K⁺ channel autoantibodies increase IKs current and are associated with QT interval shortening in dilated cardiomyopathy.

Li J, Seyler C, Wiedmann F, Schmidt C, Schweizer PA, Becker R, Katus HA, Thomas D.

Cardiovasc Res. 2013 Jun 1;98(3):496-503. doi: 10.1093/cvr/cvt046. Epub 2013 Feb 27.

PMID:
23447643
16.

Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.

Jehle J, Ficker E, Wan X, Deschenes I, Kisselbach J, Wiedmann F, Staudacher I, Schmidt C, Schweizer PA, Becker R, Katus HA, Thomas D.

Br J Pharmacol. 2013 Mar;168(5):1215-29. doi: 10.1111/bph.12002.

17.

[Cardiac two-pore-domain potassium channels (K2P): Physiology, pharmacology, and therapeutic potential].

Schmidt C, Wiedmann F, Schweizer PA, Katus HA, Thomas D.

Dtsch Med Wochenschr. 2012 Aug;137(33):1654-8. doi: 10.1055/s-0032-1305216. Epub 2012 Aug 8. Review. German.

PMID:
22875694
18.

Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid.

Jehle J, Staudacher I, Wiedmann F, Schweizer P, Becker R, Katus H, Thomas D.

Br J Pharmacol. 2012 Dec;167(7):1563-72. doi: 10.1111/j.1476-5381.2012.02117.x.

19.

Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels.

Schmidt C, Wiedmann F, Schweizer PA, Becker R, Katus HA, Thomas D.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):1003-16. doi: 10.1007/s00210-012-0780-9. Epub 2012 Jul 13.

PMID:
22790794
20.

[The meaning of Aristoteles' epikeia for medical treatment].

Sinha AM, Wiedmann F.

Wurzbg Medizinhist Mitt. 2003;22:105-12. German.

PMID:
15637803
21.

Generation and characterization of dihydroxycarbene, HO-C-OH, by neutralization/reionization mass spectrometry.

Wiedmann FA, Cai J, Wesdemiotis C.

Rapid Commun Mass Spectrom. 1994 Oct;8(10):804-7.

PMID:
8000078
22.

Further correlation of renal function with kidney biopsy in chronic renal disease.

Rosenbaum JL, Mikail M, Wiedmann F.

Am J Med Sci. 1967 Aug;254(2):156-60. No abstract available.

PMID:
4951793
23.

FREEZING WITH ETHYL CHLORIDE AS AN AID IN PREPARING SPECIMENS FOR FROZEN SECTIONS.

WIEDMANN FE.

Stain Technol. 1965 Jan;40:41. No abstract available.

PMID:
14268134
24.

Adenoacanthoma of the endometrium.

WIEDMANN FE, CRANE AR, MUCKLE CW.

Bull Phila Pa Hosp Ayer Clin Lab. 1962 May;4:57-67. No abstract available.

PMID:
14006779
25.

The value of the serum cholesterol ester determination as a test of liver function.

CHATTEN J, VIERGIVER E, WIEDMANN FE.

Bull Phila Pa Hosp Ayer Clin Lab. 1962 May;4:39-46. No abstract available.

PMID:
13878416
26.

Systemic chondromalacia (von Meyenburg's disease): a case report.

WIEDMANN FE, CRANE AR, GILL RJ.

Bull Phila Pa Hosp Ayer Clin Lab. 1959 Jun;4:45-54. No abstract available.

PMID:
13844594

Supplemental Content

Loading ...
Support Center